Literature DB >> 29234636

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.

Atsushi Hiraoka1, Kojiro Michitaka1, Takashi Kumada2, Namiki Izumi3, Masumi Kadoya4, Norihiro Kokudo5, Shoji Kubo6, Yutaka Matsuyama7, Osamu Nakashima8, Michiie Sakamoto9, Tadatoshi Takayama10, Takashi Kokudo11, Kosuke Kashiwabara12, Masatoshi Kudo13.   

Abstract

BACKGROUND/AIM: Recently, albumin-bilirubin (ALBI) scoring/grading, consisting of only albumin and total bilirubin, has been proposed. We examined the efficacy of this grading system for determining hepatic function in patients with hepatocellular carcinoma (HCC). METHODS/MATERIALS: The prognoses of 46,681 HCC patients based on results obtained from a nationwide survey conducted in Japan from 2001 to 2007 were evaluated using (1) Japan Integrated Staging (JIS), consisting of Child-Pugh classification and TNM staging (TNM), (2) modified JIS (m-JIS), consisting of liver damage grading and TNM, and (3) ALBI-TNM (ALBI-T), consisting of ALBI grading and TNM, and the results were compared. A subanalysis was also performed to define a cutoff value for ALBI scores for a more detailed stratification of hepatic function.
RESULTS: ALBI-T, JIS, and m-JIS each showed good capacity for the stratification of prognoses. Although the Akaike information criterion for ALBI-T was nearly equal to that for JIS and m-JIS, the Kaplan-Meier curves and median survival times obtained with ALBI-T were always superior to the corresponding scores. When the indocyanine green retention test (<30%) was used as an additional cutoff value for ALBI score (-2.270, area under the curve 0.828) to divide ALBI grade into 4 levels (modified ALBI [mALBI] grade), mALBI grade was able to stratify the prognosis of patients at any TNM stage in order of grade. Modified ALBI-T (mALBI-T), using mALBI grading and TNM, produced a more detailed stratification for prognosis.
CONCLUSION: The predictive value for prognosis of ALBI-T was found to be equal to that of JIS and m-JIS. In addition, mALBI grading and mALBI-T, as proposed in the present study, might provide a more detailed assessment of the hepatic function and prognosis of HCC patients.

Entities:  

Keywords:  Albumin-bilirubin grade; Hepatocellular carcinoma; Japan Integrated Staging; Modified albumin-bilirubin grade; Prognosis; TNM stage

Year:  2017        PMID: 29234636      PMCID: PMC5704689          DOI: 10.1159/000479984

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  46 in total

1.  Virtual sonographic radiofrequency ablation of hepatocellular carcinoma visualized on CT but not on conventional sonography.

Authors:  Masashi Hirooka; Hidehito Iuchi; Teru Kumagi; Shuichiro Shigematsu; Atsushi Hiraoka; Takahide Uehara; Kiyotaka Kurose; Norio Horiike; Morikazu Onji
Journal:  AJR Am J Roentgenol       Date:  2006-05       Impact factor: 3.959

2.  Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan.

Authors:  Masatoshi Kudo; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

Review 3.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

4.  Percutaneous ethanol injection therapy for hepatocellular-carcinoma (review).

Authors:  S Shiina; Y Niwa; Y Shiratori; A Terano; M Omata
Journal:  Int J Oncol       Date:  1993-04       Impact factor: 5.650

5.  Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey.

Authors:  Hienori Toyoda; Toshifumi Tada; Philip J Johnson; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Norihiro Kokudo; Yonson Ku; Shoji Kubo; Takashi Kumada; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2017-02-21       Impact factor: 7.527

6.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

7.  Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.

Authors:  Hidenori Toyoda; Takashi Kumada; Yukio Osaki; Hiroko Oka; Fumihiro Urano; Masatoshi Kudo; Takashi Matsunaga
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12       Impact factor: 11.382

8.  Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

Authors:  Sarah Berhane; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Chiaki Kagebayashi; Shinji Satomura; Nora Schweitzer; Arndt Vogel; Michael P Manns; Julia Benckert; Thomas Berg; Maria Ebker; Jan Best; Alexander Dechêne; Guido Gerken; Joerg F Schlaak; Arndt Weinmann; Marcus A Wörns; Peter Galle; Winnie Yeo; Frankie Mo; Stephen L Chan; Helen Reeves; Trevor Cox; Philip Johnson
Journal:  Clin Gastroenterol Hepatol       Date:  2016-01-13       Impact factor: 11.382

9.  Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites.

Authors:  Takahide Uehara; Masashi Hirooka; Kiyotaka Ishida; Atsushi Hiraoka; Teru Kumagi; Yoshiyasu Kisaka; Yoichi Hiasa; Morikazu Onji
Journal:  J Gastroenterol       Date:  2007-04-26       Impact factor: 7.527

10.  Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.

Authors:  Ryosuke Tateishi; Takeshi Okanoue; Naoto Fujiwara; Kiwamu Okita; Kendo Kiyosawa; Masao Omata; Hiromitsu Kumada; Norio Hayashi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2014-06-15       Impact factor: 7.527

View more
  57 in total

1.  A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.

Authors:  Masatoshi Kudo; Kwang-Hyub Han; Sheng-Long Ye; Jian Zhou; Yi-Hsiang Huang; Shi-Ming Lin; Chung-Kwe Wang; Masafumi Ikeda; Stephen Lam Chan; Su Pin Choo; Shiro Miyayama; Ann Lii Cheng
Journal:  Liver Cancer       Date:  2020-05-13       Impact factor: 11.740

2.  MR elastography, T1 and T2 relaxometry of liver: role in noninvasive assessment of liver function and portal hypertension.

Authors:  David H Hoffman; Abimbola Ayoola; Dominik Nickel; Fei Han; Hersh Chandarana; James Babb; Krishna Prasad Shanbhogue
Journal:  Abdom Radiol (NY)       Date:  2020-09

3.  ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Masashi Kudo
Journal:  Liver Cancer       Date:  2017-10-19       Impact factor: 11.740

4.  Laparoscopic versus open mesohepatectomy for patients with centrally located hepatocellular carcinoma: a propensity score matched analysis.

Authors:  Wei Li; Jun Han; Guowei Xie; Yang Xiao; Ke Sun; Kefei Yuan; Hong Wu
Journal:  Surg Endosc       Date:  2018-11-29       Impact factor: 4.584

5.  Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.

Authors:  Atsushi Hiraoka; Takashi Kumada; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Keisuke Yokohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-10-18       Impact factor: 11.740

6.  Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence.

Authors:  Weiqi Rong; Weibo Yu; Liming Wang; Fan Wu; Kai Zhang; Bo Chen; Chengli Miao; Liguo Liu; Songlin An; Changcheng Tao; Weihu Wang; Jianxiong Wu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

7.  Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kunihiko Tsuji; Koichi Takaguchi; Ei Itobayashi; Kazuya Kariyama; Hironori Ochi; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Toru Ishikawa; Yoshihiko Tachi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-06-11       Impact factor: 11.740

Review 8.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

9.  Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis.

Authors:  Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Kayoko Kasuya; Tomoya Sano; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Liver Cancer       Date:  2020-02-04       Impact factor: 11.740

10.  What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

Authors:  Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Kazuya Kariyama; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-02-25       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.